Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: Relationship between efficacy and tumor genotype in Korean patients

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 819-827

  Yoon, Dok Hyun ^a   Ryu, Min Hee ^a   Ryoo, Baek Yeol ^a   Beck, Moyeol ^a   Choi, Dae Ro ^a   Cho, Yoojin ^a   Lee, Jae Lyun ^a   Chang, Heung Moon ^a   Kim, Tae Won ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Genotype; GIST; Korean; Sunitinib

Indexed keywords

GENOMIC DNA; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; COHORT ANALYSIS; DIARRHEA; DNA SEQUENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXON; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; ONCOGENE C KIT; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PDGFRA GENE; PERITONEUM METASTASIS; PHARMACOGENETICS; PIGMENT DISORDER; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR GENE; SIDE EFFECT; SKIN TOXICITY; SOUTH KOREA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO PROGRESSION; TREATMENT DURATION; TREATMENT RESPONSE; UREMIA; VOMITING; YELLOW SKIN; ASIAN; CHI SQUARE DISTRIBUTION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; MUTATION; PHENOTYPE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE;

EID: 84862253645     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9593-1     Document Type: Article

References (31)

1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580
2. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121
3. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710
4. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357-5364
5. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
6. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY (2008) Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2): ii35-ii38
7. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23:5795-5804
8. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127-1134
9. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338
10. Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Yet al (2009) Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs
11. Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253
12. Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ et al (2006) Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol 36:17-24
13. Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM et al (2004) Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 10:3076-3081
14. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349
15. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959-1968
16. Reichardt P, Kang Y, Ruka W, Seddon B, Guerriero A, Breazna A et al (2008) Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. J Clin Oncol (Meeting Abstracts) 26:10548
17. Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schoffski P et al (2009) Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res 15:5869-5877
18. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352-5359
19. Kim TW, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM et al (2009) Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. Oncologist 14:540-547
20. Tzen CY, Wang MN, Mau BL (2008) Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors. Eur J Surg Oncol 34:563-568
21. Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P et al (2006) Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12:2622-2627
22. Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW et al (2006) Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 131:1734-1742
23. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP et al (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-340
24. Biron P, Cassier PA, Fumagalli E, Blesius A, Debiec-Rychter M, Adenis A et al (2010) Outcome of patients (pts) with PDGFRAD842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease. J Clin Oncol (Meeting Abstracts) 28:10051
25. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ et al (2009) Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 41:67-72
26. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M et al (2009) A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol
27. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524
28. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
29. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH et al (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27:4406-4412
30. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC et al (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216:64-74
31. Gramza AW, Corless CL, Heinrich MC (2009) Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 15:7510-7518